SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, today announced ...

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

Recursion co-founder & CEO Chris Gibson, PhD Roche and its Genentech subsidiary have committed up to $12 billion to Recursion in return for using its Recursion Operating System (OS) to advance ...

At a job interview on Friday, I had to write code, and one of the things that came up when we were talking about implementation of a concept was recursion. The director of the group said to me "Don't ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio ...

Recursion Pharmaceuticals is a TechBio company trying to apply artificial intelligence (AI) to the new drug-discovery process. The first placebo-controlled trial results from Recursion Pharmaceuticals ...

Recursion Pharmaceuticals' stock jumped after the FDA announced plans to replace the use of animals in drug testing. Recursion is a leader in AI-powered drug discovery and development. It remains to ...